Blarcamesine

Annovis Bio's buntanetap demonstrated significant improvements in cognitive function for early Parkinson's disease patients with mild dementia in a Phase III clinical trial, preventing cognitive decline compared to placebo.

Alzheon is set to present Phase 3 trial data for ALZ-801 in April 2025, a drug designed to prevent the formation of toxic beta-amyloid plaques in early Alzheimer's patients with the ApoE4 gene.

Anavex Life Sciences' blarcamesine demonstrates sustained cognitive and functional benefits in early Alzheimer's patients over three years of continuous oral treatment.

The 2024 J.P. Morgan Healthcare Conference kicked off with significant M&A activity, including Johnson & Johnson's $15 billion acquisition of Intra-Cellular Therapies.

The FDA has approved a monthly intravenous (IV) maintenance dose for Leqembi, offering a more convenient treatment schedule for early Alzheimer's disease.